Vancouver, British Columbia--(Newsfile Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a. . com - September 5 at 5:11 PM. , a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results. The Company's initial target indications include spinal cord injury, Alzheimer's disease and multiple. The company’s lead target. The name was changed to NervGen Pharma Corp. Find market predictions, NGENF financials and market news. 50 per unit, for aggregate gross proceeds of. (NGENF) Other OTC - Other OTC Delayed Price. August 19, 2021 – NervGen Pharma Corp. News + Insights. Vancouver, British Columbia-- (Newsfile Corp. Stock-based compensation 4,015,673 3,415,360 Unrealized foreign exchange (31,377) 16,610 Changes in non-cash working capital: Accounts receivable (1,408) 59,908. NervGen Pharma Corp. Please note that any opinions, estimates or forecasts regarding NervGen Pharma Corp. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. Vancouver, British Columbia--(Newsfile Corp. Vancouver, British Columbia--(Newsfile Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that renowned neuroscientist, Dr. Loss and comprehensive loss - - - (4,967,595). June 27, 2023 – NervGen Pharma Corp. 806 CAD. 5 million as of December 31, 2022. Nervgen Pharma Corp stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. All options. NervGen Pharma Corp. Vancouver, British Columbia-- (Newsfile Corp. 98: 52 Week High: CA$2. 2208 Follow NervGen on Twitter, LinkedIn, and Facebook. For instance, just consider the fact that Wall Street analysts are now estimating peak annual sales for Biogen’s new drug will range from $10 billion to $50 billion. , (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative. About Multiple Sclerosis Multiple sclerosis (MS) is a chronic disease in which the immune system attacks myelin (the fatty coating around neurons) in the brain and spinal cord, damaging the neurons and impairing signal transmission. 6 million. Since then, NGENF stock has increased by 19. Canada - NervGen Pharma Corp. We currently don't have sufficient analyst. ( CVE:NGEN ) by taking the. 50(-0. 07. NGENF | Complete NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and. NervGen Pharma Corp Registered Shs Reg S -144A- Accred Inv Past Events. Paradigm Capital analyst Scott McAuley is staying bullish on NervGen Pharma ( NervGen Pharma Stock Quote, Chart, News TSXV:NGEN ), maintaining a “Speculative Buy” rating and target price of $5. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that it has closed its previously announced non. The net cash burn for Q1 2021 from operating. Yield Forecast Indexes; European Futures. 92% from the latest price. NervGen Pharma Grants Stock Options Newsfile - Tue May 23, 3:41PM CDT . 23. NervGen Pharma Corp. ,. Real-time Price Updates for Nervgen Pharma Corp (NGEN-X), along with buy or sell indicators, analysis, charts, historical performance, news and moreAbout the NervGen Pharma Corp. It is backed by top experts in the field and staffed by very high-level pharma executives. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. Track NervGen Pharma Corp (NGENF) Stock Price, Quote, latest community messages, chart, news and other stock related information. View real-time stock prices and stock quotes for a full financial overview. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291 Oct 27 NervGen Pharma Corp. Financial Highlights. The net cash burn for Q2 2022 from operating activities was approximately $3. Find the latest NervGen Pharma Corp. in funding over 7 rounds. Vancouver, British Columbia--(Newsfile Corp. 05 today. - September 11, 2023) - NervGen Pharma Corp. Real-time Price Updates for Nervgen Pharma Corp (NGEN-X), along with buy or sell indicators, analysis, charts, historical performance, news and more The NervGen Pharma stock forecast is 2. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291 2022Cash and Investments: NervGen had cash and investments of $5. NervGen Pharma Corp. Stock-based compensation 3,415,360 1,293,687 Unrealized foreign exchange 16,610 133,070 Changes in non-cash working capital: Accounts receivable 59,908 (96,659). Injury can occur at any level of the spinal cord and can. - August 22, 2023) - NervGen Pharma Corp. Huitt Tracey. The Company also announced that it has granted 150,000 incentive stock options to Mr. Forecast Changes; Commodities. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. +21. - May 18, 2023) - NervGen Pharma Corp. Company Overview; 1 Valuation;. Nervgen Pharma appoints Kelly as president, CEO. November 18, 2019 – NervGen Pharma Corp. NGEN shares have been up and down since IPO-ing in March of 2019 with an issuing of ten million shares at $1. Kelly exercisable at a price of $1. NOT FOR DISTRIBUTION TO U. +0. " The 12-month stock price forecast is $21. . August 9, 2023 at 8:30 AM · 10 min read. (the “Company” or “NervGen”) is a publicly traded. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 180,000 incentive stock. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. C. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. For the upcoming trading day on Monday, 20th we expect NervGen Pharma Corp. well as stock -based compensation expense for which there was no comparable expense in the same period in the previousNervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine. (TSX-V: NGEN; OTCQX: NGENF) ('NervGen' or the 'Company'), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that all subjects (male, premenopausal and post-menopausal females) in the Phase 1 clinical trial of the Company's proprietary lead compound, NVG-291, have completed dosing. +0. NervGen Pharma Corp. 10. Currency in CAD Follow 1. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that it has been awarded a grant. The company’s lead target. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions. (the "Company" or "NervGen") and should be read in conjunction with the accompanying consolidated financial statements and related notes thereto for the period ended September 30, 2021. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. +0. Financial Highlights. 3 Bil: BMRN Biomarin Pharmaceutical Inc: Jdmlf: $15. Stock | 9UA | CA64082X2032Vancouver, British Columbia-- (Newsfile Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or. Mr. forecasts only using an unbiased methodology and our. View real-time stock prices and stock quotes for a full financial overview. 2023-04-10 09:44 ET - News Release. Make Your Research on NervGen Pharma Corp. 39 to $1. Vancouver, Canada. 2022. NervGen Pharma Corp. The market cap of NervGen is under $80 million. Vancouver, Canada. News Ideas Financials Technicals Forecast . NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. Cash Markets Overview Corn Indexes Soybean Indexes Wheat Indexes Energies Indexes Yield Forecast Indexes. Vancouver, Canada. V) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments The NervGen Pharma Corp. February 23, 2023 – NervGen Pharma Corp. Vancouver, Canada. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today is providing an update on its Phase I clinical trial and is reporting its financial. stock news by MarketWatch. Get a free in-depth analysis of NervGen Pharma (TSE:NGEN) stock. 2%. 005 USD for 2028 November 11, Saturday with technical analysis. , (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, provided an update on its Phase 1 program with NVG-291 at the Society for Neuroscience’s Neuroscience. 0 million as of March 31, 2023 Vancouver, Canada. NervGen Pharma (NGENF) has announced the appointment of Mr. - November 9, 2023) - NervGen Pharma Corp. 295$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception). 1. operates as a regenerative medicine. ’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions. 1. 06/02/2023 - 06:15 PM . 1. (TSX-V: NGEN;. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the year ended December 31, 2021. NervGen Pharma Corp. operates as a regenerative medicine company engaged in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. Ltd . NervGen’s lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial. - April 10, 2023) - NervGen Pharma Corp. 14% 1 month −1. 0100 (-0. These lofty numbers are. AZO. +3. View daily, weekly or monthly format back to when NervGen Pharma Corp. 88%. NervGen Pharma Corp. | 1,176 followers on LinkedIn. NervGen Pharma to Receive More Than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injury. The company’s. NervGen Pharma Corp. NervGen Pharma has raised a total of. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury CINervGen Pharma (NervGen Pharma Stock Quote, Charts, News, Analysts, Financials TSXV:NGEN) Rating: Speculative Buy Target Price: $6. closed the transaction. For NervGen Pharma, we've compiled three additional factors you should further research: Risks : Be aware that NervGen Pharma is showing 5 warning signs in our investment analysis , and 3 of those. 78 per share for a period of 10 years and that vest equally every month over a three-year period. Food and Drug Administration (FDA) has. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or. NervGen Pharma Corp. - May 4, 2021) - NervGen Pharma Corp. 34 0. - June 2, 2023) - NervGen Pharma Corp. NervGen Pharma Corp. 88, which is an increase of 123. Share your opinion and gain insight from other stock traders and investors. NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The net cash burn for Q2 2023 from operating activities was approximately $2. - December 15, 2020) - NervGen Pharma Corp. Financial Highlights. NOT FOR DISTRIBUTION TO U. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to. V) stock quote, history, news and other vital information to help you with your stock trading and investing. 08. All resolutions submitted for approval were passed by shareholders Vancouver, Canada, May 18, 2023 — NervGen Pharma Corp. , there are approximately 913,000 people living with MS 1 Rates of MS. ISIN. stock price gained 0. Discover NervGen Pharma's earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. Vancouver, British Columbia–(Newsfile Corp. (NGEN. is a clinical-stage biotech company. NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results. Dr Silver’s innovation offers renewed hope for the estimated 300,000 to 500,00 North Americans who dream of one-day regaining sensation and motor function in their paralysed limbs. Alnylam Pharmaceuticals Inc: Kkvsytx: $20. “We. Firm Analyst Encode Ideas, LP Hogan Mullally Paradigm Capital Scott McAuley, PhD NervGen Pharma Corp. Vancouver, British Columbia--(Newsfile Corp. NervGen Pharma is a buy, says Paradigm. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system injuries, today reported its financial results for the first quarter ended March 31, 2021. NervGen Pharma Corp. 19 at the beginning of 2023. Seasoned. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291 Oct 27 NervGen Pharma Corp. NervGen Pharma press release (OTCQX:NGENF): FY GAAP EPS of -$0. 8 million as of September 30, compared to $22. 77% 5 years 11. 5 million as of December 31, 2022. Vancouver, British Columbia--(Newsfile Corp. Latest Financial Results Quarter Ended September 30, 2023 Financial Statements MD&A Past Financial Results 2023 Quarter Ended June 30, 2023 Financial Statements MD&A Quarter Ended March 31, 2023 Financial Statements MD&A 2022 Year Ended December 31, 2022 Quarter Ended September 30, 2022 Quarter Ended June 30,. Operational Highlights for Q3 2023. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative. 8, and it has a dividend yield of ―. Receives Up to $1. 48 +11. Vancouver, Canada October 18, 2021 – NervGen Pharma Corp. 1m. 13% Year to date 10. Market Average Movement. Michael Kelly to the position of President & CEO effective April 10, 2023. Analysts publish ratings. Nervgen Pharma Corp is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. VIX Bitcoin Crude Oil Dollar Index Future Index Barron's 400 Market Data Stocks NGENF Overview NervGen Pharma Corp. Wainwright 25th Annual Global Investment Conference. NervGen Pharma Corp. Overall, NervGen Pharma’s stock price has risen by 6. 81(+0. This was offset by approximately $0. 2022, compared to $1. CI. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that all subjects (male, premenopausal. The corporate office of the Company is located atNervGen Pharma Corp. . Vancouver, British Columbia--(Newsfile Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI Oct. Cash and Investments: NervGen had cash and investments of $16. (NGEN:CA) stock. 0 million as of March 31, 2021, compared to $5. Stock Price & Overview 433 followers $1. In depth view into NGENF (NervGen Pharma) stock including the latest price, news, dividend history, earnings information and financials. 0164. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension of the expiry date. The Company's initial target indication is spinal cord injury. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for. , (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds President Biden for signing the Fiscal Year 2022. This was offset by approximately $2. Mr. Complete NervGen Pharma Corp. The company’s lead target. Today −2. July 14, 2022 at 9:05 AM · 10 min read. 064 USD Historical index on US Stock Market : A "Should I invest in NervGen Pharma stock?" "Should I trade "NGENF" stock today?" According to our live Forecast System,. ,. Currency in CAD. NGENF shares are trading down $0. 50 per unit, for aggregate gross proceeds of. Dr. , (TSX-V: NGEN) (OTCQX: NGENF), is pleased to announce the University of Cincinnati and Case Western Reserve University (CWRU) have published a pioneering preclinical study in the peer-reviewed scientific journal Cell Reports demonstrating that NervGen’s proprietary drug, NVG-291-R, promotes nervous system. Vancouver, British Columbia--(Newsfile Corp. 22%. Vancouver, British Columbia-- (Newsfile Corp. NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. Equity proceeds of CA$22M+ raised during 2022 fiscal year; Phase 1 clinical trial dosing of proprietary compound, NVG-291, is complete and data analysis is ongoingNervGen Pharma Corp. 2021 ANNUAL FINANCIAL STATEMENTS 5 1. 03% Nov 21, 2023 3:59 p. Cash and Investments: NervGen had cash and investments of $14. October 25, 2022 – NervGen. Currency in USD Follow 1. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. Stock price Other OTC Equities NGENF CA64082X2032 Biotechnology & Medical Research Delayed Other OTC. 80 -3. 9800 +0. 63% 6 months 11. If these results can be transferred to humans, it would be a milestone for many currently incurable diseases. Stable Share Price: NGEN is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 7% a week. Cash and Investments: NervGen had cash and investments of $16. com. 1 million as of June 30, 2023, compared to $22. 11%) At close: 02:05PM EST 1d 5d 1m 6m YTD 1y 5y Max NervGen Pharma's stock was trading at $1. The stock has stayed mostly between $1 and $3 over that time period, with. Phase 1 clinical trial dosing completed Phase 1b/2a clinical trial of NVG-291 in individuals with chronic and subacute spinal cord injuries expected to commence in Q3 2023 Cash and investments of $18. 70 -3. Media. Jerry Silver, inventor of NervGen's. (NGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. Daniel Mikol, will present at the 2023 International Spinal Research Trust Network Meeting being held September 14-16 in London, UK. NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab, #1-Ranked Hospital in Physical Medicine. Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic. NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates. announced that the Company has granted 285,000 incentive stock options to directors of the Company and 10,000 incentive stock options to. The stock market is getting a jolt from the inflation report. Today’s Change. Announces Executive Changes 2022: CI NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of Mr. The stock just got a big boost from new clinical results, and that bodes well for fans of NervGen Pharma (NervGen Pharma Stock Quote, Charts, News, Analysts, Financials TSXV:NGEN), according to iA. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury. (TSXV: NGEN) (OTCQX: NGENF) (" NervGen " or the " Company "), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce the closing of its previously announced public. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to. 19%) Crude Oil 76. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. 5 million from the exercise of stock options and common share purchase warrants. 0015 (+0. NervGen Pharma Grants Stock Options. Analyst Forecast According to 8 analysts, the average rating for AMAM stock is "Buy. September 5, 2023 – NervGen Pharma Corp. Nov. (TSXV:NGEN) added to S&P/TSX Venture Composite Index 2022 Vancouver - NervGen Pharma Corp. Vancouver, British Columbia--(Newsfile Corp. View real-time stock prices and stock quotes for a full financial overview. The corporate office of the Company is located atStock-based compensation - - 797,101 - 797,101 . (TSXV: NGEN). We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. 42. 92 million. 1 million as of June 30, 2023, compared to $22. What this means: InvestorsObserver gives Nervgen Pharma Corp (NGENF) an overall rank of 32, which is below average. Chronic spinal cord injury cohort results expected in mid-2024 ; Subacute spinal cord injury cohort results expected in late 2024/early 2025; Vancouver, British Columbia--(Newsfile Corp. 01 (. NervGen Pharma Corp. All options. Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. As a revolutionary treatment for Alzheimer’s disease, alone, NVG-291, offers the potential to make NervGen a future star of the biotech sector. February 24, 2020 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that members of its management team will present at the KOL Discussion on Spinal Cord Injury hosted by PropThink. The corporate office of the Company is located at 2955 Virtual Way, Suite 480, Vancouver, BC, V5M 4X6, Canada, and the registered office is located at Suite 2600,Vancouver, British Columbia--(Newsfile Corp. Newsfile Corp. Please note that any opinions, estimates or forecasts regarding NervGen Pharma Corp. stock news by MarketWatch. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 2022: CI NervGen Pharma Corp. . , (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative. C. NervGen Pharma Announces Leadership Transition. - November 8, 2023) - NervGen Pharma Corp. Menu. ,. - October 25, 2022) - NervGen Pharma Corp. For more information. 06/27/2023 - 08:30 AM . The corporate office of the Company is located atVancouver, Canada. The company’s lead target. NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself. Corporate Communications (604) 537-2094. 00 per share. The company’s lead target. Its lead product candidate is the NVG-291 that is in clinical studies for the. View real-time stock prices and stock quotes for a full financial overview. NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval View Release « Previous Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Next » NervGen Pharma has a market capitalisation of CA$114m and burnt through CA$17m last year, which is 15% of the company's market value. 22%. Forecast Changes; Commodities. See the latest NervGen Pharma Corp Ordinary Shares stock price (NGENF:PINX),. The net cash burn for Q3 2023 from operating. (NGENF) stocks, the next step is researching the company. NervGen Pharma Corp. View the. 6 million.